nCRT
Procedureneoadjuvant chemoradiotherapy
NCT Number: NCT07267767
Following thorough screening based on inclusion and exclusion criteria, patients from the two sizable medical centers were split up into two cohorts for this study. Cohort 1 served primarily as the training and internal validation set, while Cohort 2 was used for external validation of the predictive model constructed from Cohort 1. We used six distinct machine learning methodss, including DT, RF, XGBOOST, SVM, lightGBM, and SHLNN, in addition to conventional logistic regression to create the predictive model. We chose the approach with the best sensitivity and specificity by comparing the concordance index(C-index) akin to the area under the ROC curve (AUC) of these seven distinct model-building methods. The predictive model for Cohort 1 was then built using this method, and internal validation was finished. Lastly, Cohort 2 underwent external validation of the predictive model
Looking for future studies?
Notify MeAll sexes
Observational
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
(1) rectal adenocarcinoma (2) minimally invasive sphincter-preserving surgery (taTME/ISR/LAR) (3) intact baseline anal function (4) no emergent presentations or metastases.
-
Exclusion criteria
emergent presentations or metastases
-
neoadjuvant chemoradiotherapy
Body Mass Index
Distance from AV
laparoscopic and robotic surgery
tatme + isr
LCA Preserving
Prophylactic stoma
Anastomotic leakage
Time frame: 1 and 3 months after surgery
Time frame: 3 months
using LARS Score to assess the LARS situation
Northern Jiangsu People's Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07253298
Colonic Diseases, Colorectal Neoplasms
Taipei, Taiwan
View Trial DetailsNCT06936774
Colonic Diseases, Colorectal Neoplasms
Basel, Switzerland
View Trial DetailsNCT06274190
Colonic Diseases, Colorectal Neoplasms
Leuven, Vlaams-Brabant, Belgium
View Trial DetailsNCT06914245
Active Surveillance, Colonic Diseases
Leuven, Vlaams-Brabant, Belgium
View Trial Details